Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2014
At a glance
- Drugs Vancomycin (Primary) ; Vancomycin (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions
- Sponsors Savara Pharmaceuticals
- 12 Jun 2012 Results were presented, according to a Savara Pharmaceuticals media release.
- 15 May 2012 Actual patients number is 25 as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.